CoChat

Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism

Open access
Lv, Yong-Tao, Zhang, Yun, Liu, Min, Qiuwaxi, Jia-na-ti, Ashwood, Paul, Cho, Sungho Charles, Huan, Ying, Ge, Ru-Cun, Chen, Xing-Wang, Wang, Zhao-Jing, Kim, Byung-Jo, Hu, Xiang · 2013 · Journal of Translational Medicine

The DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.

Abstract

Background: Autism is a pervasive neurodevelopmental disorder. At present there are no defined mechanisms of pathogenesis and therapy is mostly limited to behavioral interventions. Stem cell transplantation may offer a unique treatment strategy for autism due to immune and neural dysregulation observed in this disease. This non-randomized, open-label, single center phase I/II trial investigated the safety and efficacy of combined transplantation of human cord blood mononuclear cells (CBMNCs) and umbilical cord-derived mesenchymal stem cells (UCMSCs) in treating children with autism. Methods: 37 subjects diagnosed with autism were enrolled into this study and divided into three groups: CBMNC group (14 subjects, received CBMNC transplantation and rehabilitation therapy), Combination group (9 subjects, received both CBMNC and UCMSC transplantation and rehabilitation therapy), and Control group (14 subjects, received only rehabilitation therapy). Transplantations included four stem cell infusions through intravenous and intrathecal injections once a week. Treatment safety was evaluated with laboratory examinations and clinical assessment of adverse effects. The Childhood Autism Rating Scale (CARS), Clinical Global Impression (CGI) scale and Aberrant Behavior Checklist (ABC) were adopted to assess the therapeutic efficacy at baseline (pre-treatment) and following treatment. Results: There were no significant safety issues related to the treatment and no observed severe adverse effects. Statistically significant differences were shown on CARS, ABC scores and CGI evaluation in the two treatment groups compared to the control at 24 weeks post-treatment (p < 0.05). Conclusions: Transplantation of CBMNCs demonstrated efficacy compared to the control group; however, the combination of CBMNCs and UCMSCs showed larger therapeutic effects than the CBMNC transplantation alone. There were no safety issues noted during infusion and the whole monitoring period. Trial registration: ClinicalTrials.gov: NCT01343511, Title “Safety and Efficacy of Stem Cell Therapy in Patients with Autism”.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1479-5876-11-196

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Enrollment and retention algorithm.
Figure 1 Enrollment and retention algorithm.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 52 references

Cited by

See all 174

Metadata

Authors
Lv, Y.-T., Zhang, Y., Liu, M., Qiuwaxi, J.-N.-T., Ashwood, P., Cho, S. C., Huan, Y., Ge, R.-C., Chen, X.-W., Wang, Z.-J., Kim, B.-J., & Hu, X.
Affiliations
  • Beike Biotechnology (China) (CN)
  • Shandong Jiaotong Hospital (CN)
  • University of California, Davis (US)
  • Korea University (KR)
Corresponding author
Hu, Xiang
Venue
Journal of Translational Medicine
Published
2013-08-27
Volume
11
Issue
1
Pages
196-196
ISSN
1479-5876 (ISSN-L)
OpenAlex
W2149113453
Cited by
174
References
53
Citations by year
2026: 6 · 2025: 11 · 2024: 14 · 2023: 13 · 2022: 14 · 2021: 16 · 2020: 23 · 2019: 13 · 2018: 11 · 2017: 13 · 2016: 13 · 2015: 15 · 2014: 12
FWCI
7.31
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Journal of Translational Medicine (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Topics
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
Keywords
autism spectrum disorder, stem cell transplantation, cord blood mononuclear cells, human umbilical cord mesenchymal stem cells, intrathecal administration, treatment safety, treatment efficacy, children, rehabilitation therapy, aberrant behavior, neurodevelopmental disorders
MeSH terms
Autistic Disorder, Child, Child, Preschool, Female, Humans, Leukocytes, Mononuclear, Male, Umbilical Cord, Treatment Outcome, Cord Blood Stem Cell Transplantation, Mesenchymal Stem Cell Transplantation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism. https://app.cochat.ai/papers/10.1186/1479-5876-11-196
The paper
Lv, Y.-T., Zhang, Y., Liu, M., Qiuwaxi, J.-N.-T., Ashwood, P., Cho, S. C., Huan, Y., Ge, R.-C., Chen, X.-W., Wang, Z.-J., Kim, B.-J., & Hu, X. (2013). Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism. Journal of Translational Medicine. https://doi.org/10.1186/1479-5876-11-196

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.